Related Experiment Video
Updated: Jan 10, 2026
Flow Cytometry-Based Isolation and Therapeutic Evaluation of Tumor-Infiltrating Lymphocytes in a Mouse Model of Pancreatic Cancer
Published on: January 17, 2025
Reprogramming Immunosuppressive Niches and the Cancer Immunity Cycle in Pancreatic Cancer with Neoantigen mRNA Plus
André E Nel1,2, Lijia Luo1,2, Yu-Pei Liao1,2
1Division of NanoMedicine, Department of Medicine, David Geffen School of Medicine, University of California, Los Angeles, California 90095, United States.
Abstract:
Pancreatic ductal adenocarcinoma (PDAC) remains among the most lethal malignancies, driven by an immune-excluded, desmoplastic tumor microenvironment (TME), a low neoantigen burden, and resistance to immune checkpoint blockade. Recent progress in immunotherapy has emerged from two complementary fronts─personalized mRNA vaccination and nanomedicine-based immune reprogramming. Clinically, the autogene cevumeran (BNT122) mRNA-lipoplex vaccine demonstrated that individualized neoantigen delivery can elicit durable, tissue-resident CD8+ T cells and prolong recurrence-free survival in resected PDAC, marking a breakthrough in restoring adaptive immunity to an otherwise "cold" tumor. Preclinically, multifunctional nanocarriers have expanded this potential to advanced disease: lipid nanoparticles (LNPs) codelivering mutant KRAS G12D mRNA and the STING agonist, cGAMP, reprogram tolerogenic hepatic antigen-presenting cells into immune activators, inducing type I interferon signaling and the ability to eradicate liver metastases in murine PDAC models. This approach overcomes the immune protective niche that promotes metastatic cancer growth in the liver. Complementary silicasome platforms (lipid bilayer coated mesoporous silica nanoparticles) encapsulating irinotecan to induce immunogenic cell death (ICD) synergize with spleen-targeting LNPs carrying KRAS mRNA and TLR7/8 agonists, thereby bridging local antigen release with systemic T-cell priming. Together, these studies establish a translational framework wherein nanoparticle-based immunotherapy can both enhance and extend the benefits of mRNA vaccines from localized to metastatic PDAC. By integrating ICD induction, neoantigen targeting, and immune niche reprogramming, these modular nanomedicine platforms offer a realistic path toward scalable, durable, and systemically effective PDAC immunotherapy.
Insights
Personalized mRNA vaccines and nanomedicine reprogram the tumor microenvironment for pancreatic cancer. These approaches enhance adaptive immunity, overcoming resistance and improving survival for pancreatic ductal adenocarcinoma (PDAC).
Area of Science:
- Oncology
- Immunotherapy
- Nanomedicine
Background:
- Pancreatic ductal adenocarcinoma (PDAC) is a lethal cancer with an immune-excluded tumor microenvironment, low neoantigen burden, and resistance to immunotherapy.
- Current immunotherapy strategies show promise through personalized mRNA vaccination and nanomedicine-based immune reprogramming.
Purpose of the Study:
- To establish a translational framework for nanoparticle-based immunotherapy to enhance and extend mRNA vaccine benefits for localized and metastatic PDAC.
- To integrate immunogenic cell death induction, neoantigen targeting, and immune niche reprogramming for effective PDAC immunotherapy.
Main Methods:
- Clinical evaluation of autogene cevumeran (BNT122) mRNA-lipoplex vaccine for neoantigen delivery in resected PDAC.
- Preclinical studies using multifunctional nanocarriers (lipid nanoparticles, silicasomes) co-delivering mRNA and immune agonists (cGAMP, TLR7/8 agonists) to reprogram tumor microenvironment and induce immunogenic cell death (ICD).
Main Results:
- Autogene cevumeran elicited durable CD8+ T cells and prolonged recurrence-free survival in resected PDAC.
- Nanocarriers reprogrammed hepatic antigen-presenting cells, induced type I interferon signaling, and eradicated liver metastases in murine PDAC models.
- Silicasome and LNP platforms synergized to bridge local antigen release with systemic T-cell priming.
Conclusions:
- Nanoparticle-based immunotherapy offers a scalable and durable approach to PDAC treatment.
- Modular nanomedicine platforms integrating ICD, neoantigen targeting, and immune reprogramming are crucial for effective PDAC immunotherapy.
- These strategies provide a realistic path toward systemically effective immunotherapy for PDAC.
Related Concept Videos
01:27Tumor Immunotherapy
01:30Cancer Vaccines
Cancer vaccines come in two categories: preventive (prophylactic) and treatment (active). Preventive vaccines, such as the Human Papillomavirus (HPV) vaccine, protect against viruses that cause certain...